REGISTER
ASCO 2026: Prof. Wenbin Li on Phase 3 Luvometinib Data in Adult NF1-PN
At ASCO 2026, Phase 3 data showed luvometinib significantly improved outcomes in adults with symptomatic, inoperable NF1-associated plexiform neurofibromas. Confirmed ORR was 43.8% versus 10.9% with placebo, median time to response was 3.9 months, and 81.0% of patients with baseline pain achieved meaningful pain reduction. Prof. Wenbin Li said the findings support a shift toward long-term, whole-course management of NF1-PN.

Luvometinib Phase 3 data demonstrate a confirmed ORR of 43.8%, a median time to response of only 3.9 months, and meaningful pain relief in 81% of patients with baseline pain.

Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder in which plexiform neurofibromas (PN) represent one of its most common and debilitating manifestations. At the 2026 ASCO Annual Meeting, pivotal results from a Phase 3 randomized, double-blind, placebo-controlled trial of luvometinib for the treatment of NF1-associated plexiform neurofibromas (NF1-PN) in adults were presented (Abstract #3017). As assessed by the Blinded Independent Review Committee (BIRC), the luvometinib arm achieved a confirmed objective response rate (ORR) of 43.8%, with a median time to response (TTR) of only 3.9 months, reflecting rapid and substantial tumor reduction. Among responders, 85.2% maintained a duration of response (DOR) of 12 months or longer, with a median DOR of 15.1 months, demonstrating durable clinical benefit. Additionally, among patients with a baseline overall tumor pain score of ≥2 points on the Numerical Rating Scale-11 (NRS-11), 81.0% achieved a pain score reduction of ≥2 points, indicating that luvometinib can meaningfully reduce the symptomatic burden of disease while controlling tumor growth. The overall safety profile was favorable and tolerability was manageable.

On this occasion, we invited the Leading Principal Investigator of this study, Professor Li Wenbin of Beijing Tiantan Hospital affiliated with Capital Medical University, to provide an in-depth interpretation of the key data and their implications for clinical practice, and to look ahead at future directions in the treatment of NF1-PN — with the aim of offering clinicians a more valuable reference for diagnosis and treatment, and further advancing the standardization of NF1-PN care.

Addressing an Unmet Need: The Long-Standing Treatment Challenges and Expectations in Adult NF1-PN

“The majority of NF1 patients harbor plexiform neurofibromas, which can cause persistent pain, disfigurement, functional impairment, and even carry a risk of malignant transformation,” Professor Li Wenbin noted. For many patients, the disease brings not only physical harm but also prolonged psychological distress and a deterioration in quality of life — a disease burden that often exceeds outside expectations. Surgery has long been a cornerstone of PN management. However, given that PNs frequently exhibit invasive growth patterns with abundant vascularity, ill-defined margins, and a tendency to encase critical neural and vascular structures, complete resection is often exceedingly difficult and the risk of postoperative recurrence remains high. “Many patients undergo surgery repeatedly — one operation after another — yet the tumor cannot be fully removed, and in some cases surgery is simply not feasible,” Professor Li stated. For symptomatic patients who are ineligible for surgery, the challenge of effectively controlling tumor progression, alleviating symptoms, and improving quality of life has long been a critical unresolved clinical problem. In recent years, MEK inhibitors have introduced a new breakthrough in the treatment of NF1-associated PN. Evidence from relevant studies has confirmed their efficacy, and both domestic and international expert consensus guidelines have recommended them as an important therapeutic option for patients who are inoperable or not candidates for surgery. Professor Li also noted, however, that pharmacotherapy is only one component of disease management. As a complex condition that spans a patient’s entire lifetime, the clinical management of NF1 continues to face numerous challenges — including how to achieve early identification and standardized intervention, how to establish long-term follow-up mechanisms, and how to coordinate multidisciplinary collaboration across neurosurgery, plastic surgery, dermatology, pain medicine, and oncology — all of which are important areas that require further refinement in current clinical practice.

Data Speak: The Luvometinib Phase 3 Trial Demonstrates Clinical Benefit Defined by Rapid Response, Durability, and Improved Quality of Life

The Phase 3 luvometinib trial for adult NF1-PN presented at the 2026 ASCO Annual Meeting is a randomized, double-blind, placebo-controlled clinical trial enrolling patients aged ≥18 years with symptomatic, inoperable NF1-associated PN. Participants were randomized 2:1 to receive either luvometinib (8 mg once daily) or placebo in 28-day cycles. Randomization was stratified by baseline overall tumor pain score (NRS-11 ≥2 or <2). The primary endpoint was confirmed ORR, as assessed by BIRC per REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) criteria. Key secondary endpoints included investigator-assessed ORR, DOR, TTR, pain improvement, and safety.

Professor Li Wenbin offered the following in-depth interpretation of the core data:

ORR: A breakthrough with both statistical and clinical significance. “The BIRC-assessed ORR in the luvometinib arm was 43.8%, compared with only 10.9% in the placebo arm — a statistically significant difference (p<0.0001),” Professor Li stated. This result confirms that luvometinib can effectively reduce tumor volume in NF1-associated PN, providing meaningful therapeutic benefit to adult patients who are ineligible for surgery.

Rapid onset of response and durable remission. The median TTR in this study was only 3.9 months. Among responders, 85.2% maintained a DOR of 12 months or longer, with a median DOR of 15.1 months (95% CI: 4.8–not reached). “Once patients achieve a response, they can sustain clinical benefit for more than one year — which is particularly important for a chronic neoplastic disease requiring long-term management, and also reduces the personal and societal burden associated with frequent treatment adjustments,” Professor Li observed.

A critical step from ‘tumor shrinkage’ to ‘improved living’. “When we treat patients, tumor reduction alone is not sufficient — improvement in quality of life is what matters most,” Professor Li emphasized, highlighting the clinical significance of pain improvement. Among patients with a baseline overall tumor pain score of ≥2 on the NRS-11, 81.0% in the luvometinib arm achieved a pain score reduction of ≥2 points, compared with 53.6% in the placebo arm.

Manageable safety profile supporting long-term use. Professor Li noted that luvometinib has already received marketing approval for the pediatric NF1-PN indication, with a well-established safety profile. In this adult Phase 3 trial, the rate of treatment discontinuation due to treatment-emergent adverse events (TEAEs) was 1.8% in both the luvometinib arm and the placebo arm, indicating excellent treatment tolerability. Common adverse events included folliculitis, creatine phosphokinase elevation, oral ulceration, and diarrhea — consistent with the known safety profile of MEK inhibitors and generally manageable. "This demonstrates that the drug is safe and manageable in clinical use, facilitating physician oversight," he noted.

Looking Ahead: From Drug Accessibility to Whole-Course Management, Advancing NF1-PN Treatment to a New Level

Based on the positive results of this Phase 3 trial, luvometinib holds considerable promise for the treatment of adult NF1-PN. Professor Li introduced that in February 2026, the New Drug Application (NDA) for luvometinib for the treatment of adult NF1-associated PN was accepted by the National Medical Products Administration (NMPA) and granted Priority Review designation. “The positive outcomes of this Phase 3 trial further enrich the body of pivotal clinical evidence. This will not only provide NF1 adult patients in China with a new, evidence-based targeted therapy option, but also contribute a Chinese solution to the global NF1 adult patient community.”

Regarding future directions in the NF1-PN field, Professor Li first emphasized the importance of whole-course disease management. “The key to comprehensive management of this disease lies in achieving early detection, early assessment, and early intervention.” As MEK inhibitors gradually expand coverage to both pediatric and adult patient populations, the therapeutic philosophy for NF1-PN is shifting from purely controlling disease toward long-term disease management.

Second, the exploration of combination therapy strategies deserves further attention. “The ORR in our study was 43.8%, which means there are still patients whose sensitivity to the drug or treatment response is limited,” Professor Li noted. Although MEK inhibitor monotherapy has demonstrated clear efficacy, a subset of patients have an inadequate response or subsequently experience disease progression. Future investigation into combinations of agents with different mechanisms of action — leveraging synergistic effects to further increase response rates, extend the duration of benefit, and delay the emergence of resistance — may offer patients greater clinical gains.

Furthermore, the development of predictive biomarkers of therapeutic response represents another important direction in advancing precision medicine for NF1-PN. “Why do some patients respond? Why do others not?” Professor Li stated that the key to answering this question lies in identifying reliable predictive biomarkers. In the future, through dynamic monitoring via molecular profiling of baseline tumor tissue and other technologies, it may be possible to achieve precise identification of patients most likely to benefit, early assessment of therapeutic response, and early warning of disease progression — further advancing NF1-PN treatment toward greater precision and individualization.

Summary

Professor Wenbin Li noted that surgical resection has historically been the primary treatment modality for NF1-PN; however, given the invasive growth pattern of these tumors, their ill-defined margins, and their abundant vascularity, complete resection is technically demanding, and some patients require repeated surgeries yet still fail to achieve adequate disease control. With the emergence of targeted therapies — and in particular the gradual expansion of treatment options across different age groups — the clinical management of NF1-PN is transitioning from a surgery-only paradigm to a multimodality treatment model, opening new possibilities for improving patients’ long-term quality of life.

Looking ahead, with the ongoing deepening of clinical application of innovative agents such as luvometinib, the continuous refinement of whole-course disease management systems, further exploration of combination therapy strategies, and advances in precision biomarker research, NF1-PN therapy is expected to progressively evolve from symptom control toward long-term, standardized management — propelling the clinical care model toward greater precision and systematization.

Expert Profile

Professor Li Wenbin

· Founding Director, Center for Comprehensive Oncology, Beijing Tiantan Hospital, Capital Medical University

· Founding Director, National Clinical Key Specialty in Neuro-oncology

· Vice President, National Health and Medical Big Data (Capital Medical University) Research Institute

· Vice President, Chinese Anti-Aging Promotion Association

· Chair, Professional Committee on Neurological Drug Clinical Research, China Pharmaceutical Innovation and Research Development Association (PhIRDA)

· Standing Member and Chair of the Innovative Drug Therapy Working Group, Science Popularization Branch, Chinese Medical Association

· Chair, Brain Tumor Expert Committee, China Cancer Foundation

· Group Leader for ICH Guideline Revision M11 Group, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

· Executive Council Member and Scientific Committee Member, Asian Society of Oncology

· Editorial Board Member, Signal Transduction and Targeted Therapy; Associate Editor, Cancer Innovation; Editor-in-Chief, Neuro-Drug Discovery

· Beijing Municipal Dual Leader Expert in Integrated Chinese and Western Medicine

· 2020 National Distinguished Physician

· Fellow of the Royal Society of Medicine (UK)

· Honorary Research Scientist, University of South Florida, USA

· Specializing in comprehensive treatment of intracranial malignant tumors; has led more than 50 domestic and international multicenter drug clinical trials; delivered oral presentations at both ESMO and ASCO for four consecutive years from 2023 to 2026; has published more than 150 academic papers.

Reference
[1] Wenbin Li, et al. Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial. 2026 ASCO, Abstract: 3017.

0
0
Loading